Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of Sorafenib, Docetaxel and Prednisone in Metastatic Prostate Cancer
2007-001318-18Phase 2Terminated
- Sponsor
- Azienda Ospedaliero-Universitaria Pisana
- Start
- May 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sorafenib in prostate cancer (PCa), sponsored by Azienda Ospedaliero-Universitaria Pisana. Primary endpoint: Number of non-progressive disease cases at 6 months. Started May 2007; status: terminated.
02
Drugs
sorafenib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2007-001318-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-001318-18.